triiodothyronine has been researched along with Adenoma, Prostatic in 3 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Men with prostate cancer had serum triiodothyronine that was significantly different than in controls (p = 0." | 5.31 | Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. ( Diamond, EJ; Droller, MJ; Lehrer, S; Stock, RG; Stone, NN, 2002) |
| " In the present study we explored whether androgens (R1881), retinoids (all-trans- and 9-cis-retinoic acid: atRA and 9cRA), deltanoids (1alpha,25-dihydroxycholecalciferol: VD3) and thyroid hormone (triiodothyronine: T3) influence the production of IGFBPs by LNCaP prostatic adenocarcinoma cells and whether the observed changes affect tumor cell growth." | 3.70 | Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells. ( Esquenet, M; Goossens, K; Manin, M; Rombauts, W; Swinnen, JV; Verhoeven, G, 1999) |
| "Men with prostate cancer had serum triiodothyronine that was significantly different than in controls (p = 0." | 1.31 | Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. ( Diamond, EJ; Droller, MJ; Lehrer, S; Stock, RG; Stone, NN, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lehrer, S | 1 |
| Diamond, EJ | 1 |
| Stone, NN | 1 |
| Droller, MJ | 1 |
| Stock, RG | 1 |
| Dunzendorfer, U | 1 |
| Weber, W | 1 |
| Russell, DH | 1 |
| Goossens, K | 1 |
| Esquenet, M | 1 |
| Swinnen, JV | 1 |
| Manin, M | 1 |
| Rombauts, W | 1 |
| Verhoeven, G | 1 |
3 other studies available for triiodothyronine and Adenoma, Prostatic
| Article | Year |
|---|---|
Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia.
Topics: Biomarkers; Biomarkers, Tumor; Humans; Immunoassay; Male; Prostatic Hyperplasia; Prostatic Neoplasms | 2002 |
Polyamines, hydrolases, (PAP, LAP, SDH, plasmin) TSH, T3, T4 and C-peptide in benign hyperplasia of the prostate.
Topics: C-Peptide; Histocytochemistry; Humans; Hydrolases; Male; Peptides; Polyamines; Prostate; Prostatic H | 1981 |
Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells.
Topics: Adenocarcinoma; Calcitriol; Cell Division; Gene Expression Regulation; Gene Expression Regulation, N | 1999 |